Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
0.2837
-0.0205 (-6.74%)
At close: Mar 13, 2026, 4:00 PM EDT
0.2775
-0.0062 (-2.19%)
After-hours: Mar 13, 2026, 7:55 PM EDT
Cue Biopharma Employees
Cue Biopharma had 41 employees as of December 31, 2024. The number of employees decreased by 12 or -22.64% compared to the previous year.
Employees
41
Change (1Y)
-12
Growth (1Y)
-22.64%
Revenue / Employee
$173,171
Profits / Employee
-$919,098
Market Cap
22.34M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 41 | -12 | -22.64% | 41 | 0 |
| Dec 31, 2023 | 53 | 1 | 1.92% | 53 | 0 |
| Dec 31, 2022 | 52 | -7 | -11.86% | 51 | 1 |
| Dec 31, 2021 | 59 | 7 | 13.46% | 57 | 2 |
| Dec 31, 2020 | 52 | 5 | 10.64% | 50 | 2 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Enlivex | 71 |
| Vistagen Therapeutics | 59 |
| Senti Biosciences | 34 |
| Longeveron | 25 |
| Passage Bio | 24 |
| Citius Pharmaceuticals | 23 |
| Daré Bioscience | 23 |
| Skye Bioscience | 16 |
CUE News
- 6 days ago - Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 - GlobeNewsWire
- 26 days ago - Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases - GlobeNewsWire
- 4 weeks ago - Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer - GlobeNewsWire
- 3 months ago - Cue Biopharma Announces Pricing of $10 Million Public Offering - GlobeNewsWire
- 3 months ago - Cue Biopharma Announces Proposed Public Offering - GlobeNewsWire
- 4 months ago - Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 months ago - Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors - GlobeNewsWire
- 5 months ago - Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates - GlobeNewsWire